CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

Table 2

Ongoing clinical trials on chemokines and chemokine receptors in patients with solid tumors.

Trial ID number	Agent description and Study design
NCT01339039; (phase I)	AMD3100 (CXCR4 antagonist) in combination with bevacizumab in patients with recurrent high grade glioma
NCT00591682; (phase I)	MSX-122 in patients with refractory metastatic or locally advanced solid tumors
NCT01545141; (phase I/II)	IFN, celecoxib, and rintatolimod [Chemokine-modulatory (CKM) regimen] as neoadjuvant therapy in patients with recurrent resectable colorectal cancer
NCT01433172; (phase I/II)	GM.CD40L Vaccine with CCL21 in patients with metastatic adenocarcinoma of the lung who must have received and completed first line therapy
NCT01015560; (phase II)	Anti-CCR2 antibody MLN1202 in treating patients with bone metastases
NCT01736813; (phase I)	Maraviroc (CCR5 inhibitor) in previously treated colorectal cancer with liver metastasis
NCT01339975	Evaluation of the role of CXCL4, CXCL4L1 and CXCR3 as biomarkers in localized, locally advanced or metastatic renal cell carcinoma
NCT00174096	Investigation of the relationship between SDF-1/CXCR4 and metastasis of laryngeal and hypopharyngeal squamous cell carcinomas
NCT00851955	Description of the role of CXCR2 ligands/CXCR2 biological axis in patients with pancreatic cancer